Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. David Taylor

Representative David Taylor (R-Ohio) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on September 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on August 14th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 8/14/2025.
• Purchased $15,001 – $50,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/14/2025.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 8/14/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 8/7/2025.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/7/2025.
• Purchased $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/7/2025.
• Sold $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/7/2025.

Eli Lilly and Company Trading Up 0.1%

NYSE:LLY opened at $736.27 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $954.00. The stock’s 50-day moving average is $745.91 and its two-hundred day moving average is $783.42. The stock has a market cap of $696.85 billion, a PE ratio of 48.12, a price-to-earnings-growth ratio of 1.02 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is 39.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $950.17.

Institutional Investors Weigh In On Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the stock. Redwood Investments LLC boosted its position in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock valued at $1,705,000 after acquiring an additional 12 shares during the period. Hobbs Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Hixon Zuercher LLC boosted its position in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after acquiring an additional 12 shares during the period. O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares during the period. Finally, Ascent Capital Management LLC boosted its position in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.